Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Ab Cellera Biologics Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$4.29 - $5.97 $7,297 - $10,154	-1,701 Reduced 4.38%	37,154 $168,000
Q4 2023 Feb 08, 2024	BUY	$3.91 - $5.93 $18,146 - $27,521	4,641 Added 13.56%	38,855 $221,000
Q2 2023 Aug 09, 2023	BUY	$5.66 - $7.59 $108,009 - $144,839	19,083 Added 126.12%	34,214 $221,000
Q1 2023 May 08, 2023	BUY	$7.31 - $11.18 $15,643 - $23,925	2,140 Added 16.47%	15,131 $114,000
Q4 2022 Feb 07, 2023	SELL	$9.48 - $14.52 $84,135 - $128,865	-8,875 Reduced 40.59%	12,991 $131,000
Q3 2022 Nov 01, 2022	BUY	$9.2 - $13.68 $82 - $123	9 Added 0.04%	21,866 $216,000
Q2 2022 Aug 04, 2022	BUY	$5.72 - $10.65 $33,456 - $62,291	5,849 Added 36.54%	21,857 $233,000
Q1 2022 May 09, 2022	BUY	$7.46 - $14.14 $13,830 - $26,215	1,854 Added 13.1%	16,008 $156,000
Q4 2021 Feb 07, 2022	BUY	$12.99 - $17.73 $92,177 - $125,812	7,096 Added 100.54%	14,154 $200,000
Q2 2021 Aug 06, 2021	BUY	$20.19 - $34.17 $142,501 - $241,171	7,058 New	7,058 $155,000

Others Institutions Holding ABCL

# of Institutions

153

Shares Held

109M

Call Options Held

153K

Put Options Held

194K

Baker Bros. Advisors LP New York, NY

27.5M
Shares

$76 Million
0.76% of portfolio
Baillie Gifford & CO

12.9M
Shares

$35.6 Million
0.03% of portfolio
Voya Investment Management LLC Atlanta, GA

10.6M
Shares

$29.3 Million
0.03% of portfolio
Prosight Management, LP Dallas, TX

9.08M
Shares

$25.1 Million
6.31% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

4.59M
Shares

$12.7 Million
0.0% of portfolio

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $787M
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account